This study reports 3-year overall survival outcomes from the CheckMate 067 trial, which compared nivolumab plus ipilimumab, nivolumab alone, and ipilimumab alone in previously untreated advanced melanoma patients. The median overall survival was not reached in the nivolumab plus ipilimumab group (38.2 months to not reached) and was 37.6 months in the nivolumab group (95% CI, 29.1 to not reached) and 19.9 months in the ipilimumab group (95% CI, 16.9 to 24.6). The 3-year overall survival rates were 58% in the nivolumab plus ipilimumab group, 52% in the nivolumab group, and 34% in the ipilimumab group. The combination therapy resulted in significantly longer progression-free survival and higher objective response rates compared to ipilimumab alone. Treatment-related adverse events were more frequent in the combination therapy group, but most resolved within 3 to 4 weeks. The findings indicate that combination therapy with nivolumab plus ipilimumab and monotherapy with nivolumab are superior to ipilimumab alone in terms of overall survival and objective response.This study reports 3-year overall survival outcomes from the CheckMate 067 trial, which compared nivolumab plus ipilimumab, nivolumab alone, and ipilimumab alone in previously untreated advanced melanoma patients. The median overall survival was not reached in the nivolumab plus ipilimumab group (38.2 months to not reached) and was 37.6 months in the nivolumab group (95% CI, 29.1 to not reached) and 19.9 months in the ipilimumab group (95% CI, 16.9 to 24.6). The 3-year overall survival rates were 58% in the nivolumab plus ipilimumab group, 52% in the nivolumab group, and 34% in the ipilimumab group. The combination therapy resulted in significantly longer progression-free survival and higher objective response rates compared to ipilimumab alone. Treatment-related adverse events were more frequent in the combination therapy group, but most resolved within 3 to 4 weeks. The findings indicate that combination therapy with nivolumab plus ipilimumab and monotherapy with nivolumab are superior to ipilimumab alone in terms of overall survival and objective response.